From speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year. Shares rose 5% in after-hours trading on Tuesday as ...

The latest company to spin out of a Stanford Medicine lab is a biotech undertaking with 37,000 employees — and none of them are human. There’s no lab space, no lunch breaks and no payroll. It’s an ...

Bipartisan legislation under review in Congress has the potential to significantly rejigger global drug development — and the biggest beneficiaries may not be American. The bill, titled the Biotech ...

The recent announcement of novel, viable viruses created by artificial intelligence (AI) was celebrated as a major advance in the fight against antibiotic resistance. But it also raised urgent ...

Mihwa Kim loved makeup so much that she became a host on a beauty home shopping show in South Korea — comparing, testing and promoting dozens of products on television. Then in 2013, her career was ...

As Legend Biotech's CEO suddenly resigned, the search is underway to identify a permanent successor. (Gerd Altmann/Pixabay) In a sudden leadership shift, Legend Biotech announced that its CEO, Ying ...

Which emerging hubs could become dominant forces in biotech in the decades ahead? (Ayla Ellison ) Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of ...

Dealmaking is back with a vengeance in the pharmaceutical sector this year. According to a report by PwC, there were more than $65 billion in pharma and life sciences mergers & acquisitions in the ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic. Venture capital in biopharma ...